SecBot SecBot
8-K ·Filed Nov 2, 2026

KRYS

Krystal Biotech, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed14d 16h ago SEC0001711279-26-000072
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The revenue beat and narrowed expense guidance signal operational leverage. The $400M buyback (about 4% of market cap) adds a capital return element. Watch for KB803 IOLITE top-line results in February 2027 and KB111 interim data before year-end.

DirectionBullish
Confidencehigh
Horizonweeks

KB113

● Neutral Named in this 8-K
Impact
Phase
Pilot study (proof-of-concept, equivalent to early Phase 1/2)
Time to market
KB113 is in early-stage development with no registered Phase 2/3 trial and no defined regulatory timeline. The company is in discussions with the FDA to determine the clinical development plan. If a pivotal program is agreed upon and initiated in 2027, potential approval would likely be several years away, barring a breakthrough or accelerated pathway.
Next catalyst
None dated

What to watchWatch for Krystal Biotech's announcement of FDA alignment on KB113's clinical development plan, which will define whether the program advances into a registrational trial or requires additional dose-finding studies. The small pilot (n=3) provides proof-of-concept but the regulatory path and timeline remain undefined, making KB113 a pipeline story rather than a near-term catalyst.

Price Chart

Loading chart...

Executive Summary

Krystal Biotech reported Q3 2026 VYJUVEK revenue of $127.3M, up 30% YoY, above the $126.5M consensus. GAAP diluted EPS was $2.05, above the $1.92 consensus. The company also announced a $400M share repurchase program and narrowed FY 2026 non-GAAP R&D and SG&A expense guidance to $155M-$165M from $175M-$195M. Positive early clinical data for KB113 in Gorlin syndrome was highlighted.

Key Financial Metrics

EPS
$2.05
est $1.92 · +6.8%
Revenue
$127.3M
est $126.5M · +0.7% · +30.2% YoY
Rating
beat
Gross Margin
94%

Key Facts

  • Q3 2026 VYJUVEK global net product revenue of $127.3M, up 30% YoY from $97.8M
  • GAAP diluted EPS of $2.05 vs consensus of $1.92
  • Board authorized share repurchase program of up to $400 million
  • FY 2026 non-GAAP R&D and SG&A expense guidance narrowed to $155M-$165M from $175M-$195M
  • KB113 pilot study showed >80% of assessed BCC lesions with clinical regression in Gorlin syndrome patients
  • Cash and investments totaled $1.2 billion as of September 30, 2026
  • Pricing negotiations completed in Germany and Italy; Italy launch expected in early 2027

Financial Impact

Q3 revenue of $127.3M beat consensus by approximately 0.6%; EPS of $2.05 beat consensus by approximately 6.8%

revenueepscash positionshare repurchase authorization

Risk Factors

  • Net income declined YoY from $79.4M to $63.1M due to a $48.5M swing in income tax expense
  • KB801 enrollment slower than expected due to narrow eligibility criteria and placebo-controlled design
  • Pricing negotiations in France not expected until at least 2027

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001711279-26-000072
Document: krys-20261102.htm0001711279-26-000072
Document: 0001711279-26-000072-index-headers.html0001711279-26-000072
Document: 0001711279-26-000072-index.html0001711279-26-000072
Document: 0001711279-26-000072.txt0001711279-26-000072
8-K Data (Synthetic)0001711279-26-000072

Track record

18 reports on KRYS

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +26.60% at T+60 after the May 4, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 2, 202614d ago 8-K Bullish 6/10 Viewing No price data
  2. Nov 2, 202614d ago Press Release Bullish 6/10 Entry $295.90 Now $297.90 +0.68% settles Dec 1
  3. Oct 30, 202617d ago SC 13G/A Bearish 5/10 Entry $332.29 Now $297.90 +10.35% settles Nov 30
  4. Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
  5. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
  6. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
  7. Oct 21, 202626d ago Institutional Cluster Neutral 3/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
  8. Oct 15, 20264w ago 8-K Bullish 6/10 Entry $330.00 to $305.68 Now $297.90 −9.73% ▼ −7.37% −5.47% vs SPY
  9. Sep 4, 202610w ago Insider Cluster Bearish 5/10 Entry $351.26 to $326.81 Now $297.90 +15.19% ▲ +6.96% +8.67% vs SPY
  10. Aug 14, 202613w ago 144 Neutral 2/10 Entry $335.73 to $336.68 Now $297.90 −11.27% ▲ +0.28% +2.26% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens Wed (10h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026